All Stories

  1. Reply to: “DHEA and progesterone have a protective effect on ribavirin-induced hemolysis”

    Article • Journal of Hepatology, April 2014, Elsevier

    Peter Ferenci

  2. Whom and how to screen for Wilson disease

    Article • Expert Review of Gastroenterology & Hepatology, March 2014, Taylor & Francis

    Peter Ferenci

  3. Phenotype–genotype correlations in patients with Wilson's disease

    Article • Annals of the New York Academy of Sciences, February 2014, Wiley

    Peter Ferenci

  4. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa‐2a (40kD)/ribavirin

    Article • Liver International, January 2014, Wiley

    Peter Ferenci

  5. Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin?

    Article • Journal of Infectious Diseases and Therapy, January 2014, OMICS Publishing Group

    Peter Ferenci

  6. Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients

    Article • Hepatology International, November 2013, Springer Science + Business Media

    Peter Ferenci

  7. Treatment of Chronic Hepatitis C, Genotype 4

    Article • Current Hepatology Reports, August 2013, Springer Science + Business Media

    Peter Ferenci

  8. Efficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease

    Article • Clinical Gastroenterology and Hepatology, August 2013, Elsevier

    Peter Ferenci

  9. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C

    Article • Liver International, July 2013, Wiley

    Peter Ferenci

  10. Silibinin: An old drug in the high tech era of liver transplantation

    Article • Journal of Hepatology, March 2013, Elsevier

    Peter Ferenci

  11. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection

    Article • Hepatology, March 2013, Wolters Kluwer Health

    Peter Ferenci

  12. Silymarin for HCV infection

    Article • Antiviral Therapy, January 2013, International Medical Press

    Peter Ferenci

  13. Treatment With Silymarin for Hepatitis C Virus

    Article • JAMA, November 2012, American Medical Association (AMA)

    Peter Ferenci

  14. Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C

    Article • Journal of Hepatology, September 2012, Elsevier

    Peter Ferenci

  15. Response guided therapy in patients with chronic hepatitis C – Yesterday, today and tomorrow

    Article • Best Practice & Research Clinical Gastroenterology, August 2012, Elsevier

    Peter Ferenci

  16. Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study

    Article • Journal of Human Genetics, July 2012, Springer Science + Business Media

    Peter Ferenci

  17. The multiplicity of divergence mechanisms in a single evolving population

    Article • June 2012, Springer Science + Business Media

    Peter Ferenci, Professor Peter Richard Reeves

  18. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin

    Article • Journal of Hepatology, June 2012, Elsevier

    Peter Ferenci

  19. Understanding silibinin’s modes of action against HCV using viral kinetic modeling

    Article • Journal of Hepatology, May 2012, Elsevier

    Peter Ferenci

  20. Wilson disease

    Article • April 2012, Wiley

    Peter Ferenci

  21. Treatment options for anti-HCV treatment-experienced patients

    Article • Clinical Liver Disease, April 2012, Wolters Kluwer Health

    Peter Ferenci

  22. Defining Wilson Disease Phenotypes: From the Patient to the Bench and Back Again

    Article • Gastroenterology, April 2012, Elsevier

    Peter Ferenci

  23. Treatment of Chronic Hepatitis C Genotype 1 Patients at An Academic Center in Europe Involved in Prospective, Controlled Trials

    Article • Hepatology, January 2012, Wolters Kluwer Health

    Peter Ferenci

  24. Treatment of chronic hepatitis C – are interferons really necessary?

    Article • Liver International, December 2011, Wiley

    Peter Ferenci

  25. Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms

    Article • Journal of Inherited Metabolic Disease, December 2011, Wiley

    Peter Ferenci

  26. IL28B and interferon‐gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV‐HCV‐coinfected patients

    Article • European Journal of Clinical Investigation, November 2011, Wiley

    Peter Ferenci

  27. Polymorphism of methylenetetrahydrofolate reductase as disease modifier – A déjà-vu in Wilson disease?

    Article • Journal of Hepatology, October 2011, Elsevier

    Peter Ferenci

  28. Hepatitis C: Personalisierte Therapie

    Article • Wiener klinisches Magazin, October 2011, Springer Science + Business Media

    Peter Ferenci

  29. Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

    Article • Journal of Hepatology, June 2011, Elsevier

    Peter Ferenci

  30. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin

    Article • Journal of Hepatology, May 2011, Elsevier

    Peter Ferenci

  31. Zinc Monotherapy Is Not as Effective as Chelating Agents in Treatment of Wilson Disease

    Article • Gastroenterology, April 2011, Elsevier

    Peter Ferenci

  32. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C

    Article • Journal of Hepatology, March 2011, Elsevier

    Peter Ferenci

  33. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection

    Article • Antiviral Therapy, January 2011, International Medical Press

    Peter Ferenci

  34. Intravenous silibinin as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin combination therapy

    Article • Antiviral Therapy, January 2011, International Medical Press

    Peter Ferenci

  35. Dynamic Coinfection with Multiple Viral Subtypes in Acute Hepatitis C

    Article • The Journal of Infectious Diseases, December 2010, Oxford University Press (OUP)

    Peter Ferenci, Professor Peter Karayiannis

  36. Hepatic Encephalopathy: Treatment

    Article • July 2010, Wiley

    Peter Ferenci

  37. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease

    Article • Journal of Inherited Metabolic Disease, June 2010, Wiley

    Peter Ferenci

  38. Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy

    Article • Journal of Hepatology, June 2010, Elsevier

    Peter Ferenci

  39. Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy

    Article • European Journal of Radiology, June 2010, Elsevier

    Peter Ferenci

  40. 4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009

    Article • Wiener klinische Wochenschrift, May 2010, Springer Science + Business Media

    Peter Ferenci

  41. A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis

    Article • Liver International, April 2010, Wiley

    Peter Ferenci

  42. Treatment of chronic hepatitis C—how much interferon is enough?

    Article • Nature Reviews Gastroenterology & Hepatology, April 2010, Springer Science + Business Media

    Peter Ferenci

  43. Hepatocyte GP73 expression in Wilson disease

    Article • Journal of Hepatology, September 2009, Elsevier

    Peter Ferenci

  44. Experimental models of hepatic encephalopathy: ISHEN guidelines

    Article • Liver International, July 2009, Wiley

    Peter Ferenci

  45. Silibinin (Legalon-SIL) Inhibits HCV Replication In Vitro

    Article • Antiviral Research, May 2009, Elsevier

    Peter Ferenci

  46. A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration #

    Article • Hepatology, April 2009, Wolters Kluwer Health

    Peter Ferenci

  47. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more? #

    Article • Hepatology, February 2009, Wolters Kluwer Health

    Peter Ferenci

  48. Peter Ferenci, MD

    Article • Journal of Hepatology, October 2008, Elsevier

    Peter Ferenci

  49. Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial

    Article • Wiener klinische Wochenschrift, October 2008, Springer Science + Business Media

    Peter Ferenci, Martin Posch

  50. Reply

    Article • Hepatology, August 2008, Wolters Kluwer Health

    Peter Ferenci

  51. W1002 Silibinin Is a Potent Antiviral Agent in Patients with Chronic HCV Infection Not Responding to Peginterferon/Ribavirin Therapy

    Article • Gastroenterology, April 2008, Elsevier

    Peter Ferenci

  52. Depression in chronic hepatitis: the virus, the drug, or the ethnic background?

    Article • Liver International, March 2008, Wiley

    Peter Ferenci

  53. Evolution of Crohn’s disease-associated Nod2 mutations

    Article • Immunogenetics, February 2008, Springer Science + Business Media

    Peter Ferenci

  54. Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful?

    Article • Wiener klinische Wochenschrift, January 2008, Springer Science + Business Media

    Peter Ferenci

  55. MARS and the failing liver—Any help from the outer space?

    Article • Hepatology, December 2007, Wolters Kluwer Health

    Peter Ferenci

  56. Treatment Options for Hepatic Encephalopathy: A Review

    Article • Seminars in Liver Disease, August 2007, Thieme Publishing Group

    Peter Ferenci

  57. An Algorithm for the Management of Hepatic Encephalopathy

    Article • Seminars in Liver Disease, August 2007, Thieme Publishing Group

    Peter Ferenci

  58. Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson’s disease in children

    Article • Journal of Hepatology, August 2007, Elsevier

    Peter Ferenci

  59. Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s

    Article • Journal of Hepatology, July 2007, Elsevier

    Peter Ferenci

  60. Late-Onset Wilson’s Disease

    Article • Gastroenterology, April 2007, Elsevier

    Peter Ferenci

  61. Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients

    Article • BMC Cancer, March 2007, Springer Science + Business Media

    Peter Ferenci

  62. Novel mutations of the ATP7B gene among 109 Hungarian patients with Wilson??s disease

    Article • European Journal of Gastroenterology & Hepatology, February 2007, Wolters Kluwer Health

    Peter Ferenci

  63. Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia

    Article • Wiener klinische Wochenschrift, October 2006, Springer Science + Business Media

    Peter Ferenci

  64. The Host or the Virus? Impact of Genetic Factors on the Outcome of Hepatitis C Virus Infection

    Article • Gastroenterology, September 2006, Elsevier

    Peter Ferenci

  65. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing

    Article • Human Genetics, June 2006, Springer Science + Business Media

    Peter Ferenci

  66. Wilson Disease

    Article • January 2006, Elsevier

    Peter Ferenci

  67. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

    Article • Journal of Hepatology, January 2006, Elsevier

    Peter Ferenci

  68. Wilson Disease

    Article • Metabolic Brain Disease, December 2005, Springer Science + Business Media

    Peter Ferenci

  69. Response to letter from Professor Peter Ferenci

    Article • Digestive and Liver Disease, October 2005, Elsevier

    Peter Ferenci

  70. Prediction of Progression to Cirrhosis by a Glutathione S-Transferase P1 Polymorphism in Subjects With Hereditary Hemochromatosis

    Article • Archives of Internal Medicine, September 2005, American Medical Association (AMA)

    Peter Ferenci

  71. Sonographic diagnosis of coeliac disease in a case with suspected acute liver failure

    Article • European Journal of Gastroenterology & Hepatology, September 2005, Wolters Kluwer Health

    Peter Ferenci

  72. Wilson’s Disease

    Article • Clinical Gastroenterology and Hepatology, August 2005, Elsevier

    Peter Ferenci

  73. Diagnostic Value of Quantitative Hepatic Copper Determination in Patients With Wilson’s Disease

    Article • Clinical Gastroenterology and Hepatology, August 2005, Elsevier

    Peter Ferenci

  74. Successful Treatment of Chronic Hepatitis D with a Short Course of Peginterferon alfa-2a

    Article • The American Journal of Gastroenterology, July 2005, Wolters Kluwer Health

    Peter Ferenci

  75. Dysfunction of the liver affects the sense of smell

    Article • Wiener klinische Wochenschrift, January 2005, Springer Science + Business Media

    Peter Ferenci

  76. Increased C282Y Heterozygosity in Gestational Diabetes

    Article • Fetal Diagnosis and Therapy, January 2005, Karger Publishers

    Peter Ferenci

  77. Pathophysiology and Clinical Features of Wilson Disease

    Article • Metabolic Brain Disease, December 2004, Springer Science + Business Media

    Peter Ferenci

  78. Current Treatment for chronic hepatitis C

    Article • Current Treatment Options in Gastroenterology, December 2004, Springer Science + Business Media

    Peter Ferenci

  79. Hepatic Encephalopathy

    Article • November 2004, Wiley

    Peter Ferenci

  80. Transjugular intrahepatic portosystemic shunt in Vienna – A decade later

    Article • Wiener klinische Wochenschrift, September 2004, Springer Science + Business Media

    Peter Ferenci

  81. Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine

    Article • Wiener klinische Wochenschrift, August 2004, Springer Science + Business Media

    Peter Ferenci

  82. Predictors of Response to Therapy for Chronic Hepatitis C

    Article • Seminars in Liver Disease, May 2004, Thieme Publishing Group

    Peter Ferenci

  83. Treatment of chronic viral hepatitis

    Article • Best Practice & Research Clinical Gastroenterology, January 2004, Elsevier

    Peter Ferenci

  84. Protease inhibitors for treatment of chronic hepatitis C—a new target for the magic bullet identified

    Article • Journal of Hepatology, January 2004, Elsevier

    Peter Ferenci

  85. Prediction of Spontaneous Viral Clearance in Acute Hepatitis C by Viral Load Measurements

    Article • Hepatology, June 2003, Wolters Kluwer Health

    Peter Ferenci

  86. Diagnosis and phenotypic classification of Wilson disease1

    Article • June 2003

    Peter Ferenci

  87. Early viral kinetics in chronic hepatitis C virus genotype 4 infection

    Article • Gastroenterology, April 2003, Elsevier

    Peter Ferenci

  88. Suppression of hematopoiesis during therapy with different IFN-α mono- and combination therapy regimes

    Article • Gastroenterology, April 2003, Elsevier

    Peter Ferenci

  89. Centrilobular necrosis in autoimmune hepatitis: A histological feature associated with an acute onset of disease

    Article • Gastroenterology, April 2003, Elsevier

    Peter Ferenci

  90. Hepatitis C viral dynamics: basic concept and clinical significance

    Article • Journal of Clinical Virology, December 2002, Elsevier

    Peter Ferenci

  91. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C

    Article • Hepatology, November 2002, Wolters Kluwer Health

    Peter Ferenci

  92. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

    Article • The American Journal of Gastroenterology, November 2002, Wolters Kluwer Health

    Peter Ferenci

  93. Liver pathology in compound heterozygous patients for hemochromatosis mutations

    Article • August 2002, Wiley

    Peter Ferenci

  94. Rapid suppression of hematopoiesis by standard or pegylated interferon-α

    Article • Gastroenterology, July 2002, Elsevier

    Peter Ferenci

  95. Primary IFN-resistance in chronic hepatitis C virus genotype 4 infection

    Article • Journal of Hepatology, April 2002, Elsevier

    Peter Ferenci

  96. Hematological changes during IFN/ribavirin combination therapy in patients with chronic hepatitis C

    Article • Journal of Hepatology, April 2002, Elsevier

    Peter Ferenci

  97. Primary interferon resistance and treatment response in chronic hepatitis C infection

    Article • The Lancet, March 2002, Elsevier

    Peter Ferenci

  98. Hepatic transport systems

    Article • Journal of Gastroenterology and Hepatology, February 2002, Wiley

    Peter Ferenci

  99. Common mutations of ATP7B in Wilson disease patients from Hungary

    Article • American Journal of Medical Genetics, January 2002, Wiley

    Peter Ferenci

  100. Postcremation diagnosis from an electric shaver

    Article • The Lancet, July 2001, Elsevier

    Peter Ferenci

  101. Wilson disease in two consecutive generations: an exceptional family

    Article • The American Journal of Gastroenterology, July 2001, Wolters Kluwer Health

    Peter Ferenci

  102. Portal hypertension

    Article • European Journal of Gastroenterology & Hepatology, April 2001, Wolters Kluwer Health

    Peter Ferenci

  103. Effect of pegylated (PEG 40kd) interferon (IFN)α-2a on early virus elimination in patients infected with HCV subtype 1

    Article • Gastroenterology, April 2001, Elsevier

    Peter Ferenci

  104. TWELVE MONTHS OF LAMIVUDINE TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION IN RENAL TRANSPLANT RECIPIENTS12

    Article • Transplantation, November 2000, Wolters Kluwer Health

    Peter Ferenci

  105. His1069Gln mutation in Hungarian patients with Wilson's disease

    Article • The American Journal of Gastroenterology, September 2000, Wolters Kluwer Health

    Peter Ferenci

  106. Genetic testing and pedigree analysis in an exceptional family with Wilson's disease. How far should we go by genetic analysis?

    Article • The American Journal of Gastroenterology, September 2000, Wolters Kluwer Health

    Peter Ferenci

  107. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation

    Article • European Journal of Gastroenterology & Hepatology, August 2000, Wolters Kluwer Health

    Peter Ferenci

  108. Letters to the Editor

    Article • Journal of Hepatology, May 2000, Elsevier

    Peter Ferenci

  109. Wilson's disease in eastern germany: High frequency of the H1069Q mutation and correlation with the neurological manifestation

    Article • Gastroenterology, April 2000, Elsevier

    Peter Ferenci

  110. Treatment with amantadine +ribavirin +interferon in patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy

    Article • Gastroenterology, April 2000, Elsevier

    Peter Ferenci

  111. Differential thrombopoietin response to treatment-induced thrombocytopenia: IFN VS. IFN-ribavirin VS. PEG-IFN

    Article • Gastroenterology, April 2000, Elsevier

    Peter Ferenci

  112. Cognitive brain function is subclinically impaired in patients with chronic hepatitis C - does hepatitis C affect the brain?

    Article • Gastroenterology, April 2000, Elsevier

    Peter Ferenci

  113. Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C

    Article • Gastroenterology, April 2000, Elsevier

    Peter Ferenci

  114. Mutations of the Wilson's disease gene in Austria-genotype/phenotype correlations and feasibility of mutation analysis

    Article • Gastroenterology, April 2000, Elsevier

    Peter Ferenci

  115. Genetic testing and pedigree analysis in an exceptional family with Wilson's disease. How far should we go by genetic analysis?

    Article • Gastroenterology, April 2000, Elsevier

    Peter Ferenci

  116. Prevalence and Distribution of Hepatitis C Subtypes in Patients with Opioid Dependence

    Article • European Addiction Research, January 2000, Karger Publishers

    Peter Ferenci, Dr Reinhold Jagsch

  117. Partial pressure of ammonia versus ammonia in hepatic encephalopathy

    Article • Hepatology, January 2000, Wolters Kluwer Health

    Peter Ferenci

  118. Image of the month

    Article • Gastroenterology, May 1999, Elsevier

    Peter Ferenci

  119. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease

    Article • European Journal of Gastroenterology & Hepatology, March 1999, Wolters Kluwer Health

    Peter Ferenci

  120. CLINICAL ISSUES IN THE MANAGEMENT OF ALCOHOLIC LIVER DISEASE

    Article • Clinics in Liver Disease, November 1998, Elsevier

    Peter Ferenci

  121. Effects of testosterone suppression on serum levels of hepatitis B surface antigen and HBV‐DNA in men

    Article • Liver International, June 1998, Wiley

    Peter Ferenci

  122. WILSON'S DISEASE

    Article • Clinics in Liver Disease, February 1998, Elsevier

    Peter Ferenci

  123. Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin

    Article • Journal of Hepatology, August 1997, Elsevier

    Peter Ferenci

  124. Dose increase augments response rate to interferon-α in chronic hepatitis C

    Article • Digestive Diseases and Sciences, December 1996, Springer Science + Business Media

    Peter Ferenci

  125. Newer Approaches to Therapy of Hepatic Encephalopathy

    Article • Seminars in Liver Disease, January 1996, Thieme Publishing Group

    Peter Ferenci

  126. Treatment of Hepatic Encephalopathy in Patients with Cirrhosis of the Liver

    Article • Digestive Diseases, January 1996, Karger Publishers

    Peter Ferenci

  127. Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis

    Article • Gastroenterology, December 1995, Elsevier

    Peter Ferenci

  128. Dental and periodontal disease in patients with cirrhosis - role of etiology of liver disease

    Article • Journal of Hepatology, May 1995, Elsevier

    Peter Ferenci

  129. Vitamin D status in outpatients with Crohnʼs disease

    Article • European Journal of Gastroenterology & Hepatology, June 1994, Wolters Kluwer Health

    Peter Ferenci

  130. Folate Absorption in Crohn’s Disease

    Article • Digestion, January 1994, Karger Publishers

    Peter Ferenci

  131. Neuropharmacologic Modulation of Hepatic Encephalopathy: Experimental and Clinical Data

    Article • January 1994, Springer Science + Business Media

    Peter Ferenci

  132. Energy metabolism in acute hepatic failure

    Article • Gastroenterology, November 1993, Elsevier

    Peter Ferenci, Dr Kurt Lenz

  133. Detailed evaluation of evoked potentials in Wilson's disease

    Article • Electroencephalography and Clinical Neurophysiology, February 1992, Elsevier

    Peter Ferenci

  134. Beneficial effect of pharmacological modulation of the GABAA-benzodiazepine receptor on hepatic encephalopathy in the rat: Comparison with uremic encephalopathy

    Article • Hepatology, December 1991, Wolters Kluwer Health

    Peter Ferenci

  135. The role of methanethiol in the pathogenesis of hepatic encephalopathy

    Article • Hepatology, March 1991, Wolters Kluwer Health

    Peter Ferenci

  136. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide—induced acute liver failure

    Article • Hepatology, October 1990, Wolters Kluwer Health

    Peter Ferenci

  137. Energy Metabolism in Patients With Acute and Chronic Liver Disease

    Article • Hepatology, March 1990, Wolters Kluwer Health

    Peter Ferenci, Dr Kurt Lenz

  138. Benzodiazepine Antagonist in the Treatment of Human Hepatic Encephalopathy

    Article • January 1990, Springer Science + Business Media

    Peter Ferenci

  139. Cerebral glutamine metabolism: Study of modulatory effects of glutamine on γ-aminobutyric acid-ergic neurotransmission

    Article • Metabolism, August 1989, Elsevier

    Peter Ferenci

  140. Hepatologie

    Article • Journal of Hepatology, March 1989, Elsevier

    Peter Ferenci

  141. Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy

    Article • Journal of Hepatology, March 1989, Elsevier

    Peter Ferenci

  142. Treatment Of Hepatic Encephalopathy With The Benzodiazepine Antagonist Flumazenil

    Article • January 1989, Springer Science + Business Media

    Peter Ferenci

  143. Overestimation of serum concentrations of γ-aminobutyric acid in patients with hepatic encephalopathy by the γ-aminobutyric acid-radioreceptor assay

    Article • Hepatology, January 1988, Wolters Kluwer Health

    Peter Ferenci

  144. Long-term follow-up study of asymptomatic hbsag-positive voluntary blood donors in austria: A clinical and histologic evaluation of 242 cases

    Article • Hepatology, March 1987, Wolters Kluwer Health

    Peter Ferenci

  145. The GABA Hypothesis of the Pathogenesis of Hepatic Encephalopathy: Current Status

    Article • January 1987, Springer Science + Business Media

    Peter Ferenci

  146. Lack of evidence for impaired dopamine receptor function in experimental hepatic coma in the rabbit

    Article • Neuroscience Letters, March 1986, Elsevier

    Peter Ferenci

  147. A nonlinear kinetic model of γ-aminobutyric acid metabolism in a rabbit model of acute liver failure

    Article • Mathematical Biosciences, July 1985, Elsevier

    Peter Ferenci

  148. The Neurobiology of Hepatic Encephalopathy

    Article • Hepatology, November 1984, Wolters Kluwer Health

    Peter Ferenci

  149. Impaired plasma amino‐acid clearance in patients with cirrhosis of the liver and portocaval shunt—its relation to insulin resistance

    Article • European Journal of Clinical Investigation, August 1984, Wiley

    Peter Ferenci

  150. Changes in the Status of Neurotransmitter Receptors in a Rabbit Model of Hepatic Encephalopathy

    Article • Hepatology, March 1984, Wolters Kluwer Health

    Peter Ferenci

  151. Relative incidence of primary liver cancer in cirrhosis in Austria. Etiological considerations

    Article • Liver International, February 1984, Wiley

    Peter Ferenci

  152. Changes in Glutamate Receptors on Synaptic Membranes Associated with Hepatic Encephalopathy or Hyperammonemia in the Rabbit

    Article • Hepatology, January 1984, Wolters Kluwer Health

    Peter Ferenci

  153. bolism of the Inhibitory Neurotransmitter γ-Aminobutyric Acid in a Rabbit Model of Fulminant Hepatic Failure

    Article • Hepatology, July 1983, Wolters Kluwer Health

    Peter Ferenci